Loss of hepatitis A virus (HAV) antibodies after peripheral stem cell transplantation (PSCT)

Dignani, María Cecilia; Miceli, Maria-Augusta; Rosa, Carolyn M. De; Gatica, Jimena; Martínez-Rolón, Juliana; Pizzolato, Marco

doi:10.1038/sj.bmt.1704028

Cited by 15 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are a number of commercially available assays for the detection of IgM and total anti-HAV (71,122,188). IgM, IgA, and IgG anti-HAV are usually present at the onset of symptoms (Fig.…”

Section: Detection Of Hav-specific Antibodiesmentioning

confidence: 99%

Diagnosis of Hepatitis A Virus Infection: a Molecular Approach

et al. 2006

View full text Add to dashboard Cite

SUMMARY Current serologic tests provide the foundation for diagnosis of hepatitis A and hepatitis A virus (HAV) infection. Recent advances in methods to identify and characterize nucleic acid markers of viral infections have provided the foundation for the field of molecular epidemiology and increased our knowledge of the molecular biology and epidemiology of HAV. Although HAV is primarily shed in feces, there is a strong viremic phase during infection which has allowed easy access to virus isolates and the use of molecular markers to determine their genetic relatedness. Molecular epidemiologic studies have provided new information on the types and extent of HAV infection and transmission in the United States. In addition, these new diagnostic methods have provided tools for the rapid detection of food-borne HAV transmission and identification of the potential source of the food contamination.

show abstract

“…There are a number of commercially available assays for the detection of IgM and total anti-HAV (71,122,188). IgM, IgA, and IgG anti-HAV are usually present at the onset of symptoms (Fig.…”

Section: Detection Of Hav-specific Antibodiesmentioning

confidence: 99%

Diagnosis of Hepatitis A Virus Infection: a Molecular Approach

et al. 2006

View full text Add to dashboard Cite

show abstract

“…2,3 Post transplant reimmunization guidelines have indicated the inactivated HAV vaccine for susceptible HSCT recipients living in or traveling to areas where HAV infection is endemic. 4 However, few data are available concerning the loss of specific HAV immunity over time 5 and ultimately, the need of including inactivated hepatitis A vaccine in reimmunization protocols of developing countries.…”

Section: Introductionmentioning

confidence: 99%

Loss of hepatitis A virus antibodies after bone marrow transplantation

Godoi

Souza

Cakmak

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Reimmunization guidelines have recommended the inactivated HAV vaccine for hematopoietic stem cell transplant (HSCT) recipients living in or traveling to areas where hepatitis A is endemic. As a shift from high to medium hepatitis A endemicity has been observed in several countries in Latin America, we conducted a retrospective study to evaluate the prevalence of hepatitis A pre-bone marrow transplant (BMT) and the loss of specific antibodies in consecutive stored serum samples from 77 BMT recipients followed up from 82 to 1530 days. The prevalence of HAV antibodies was 92.2% before BMT. As vaccine was not available in Brazil when the samples were taken, it was assumed that this prevalence reflects natural infection. Survival analysis showed that the probability of becoming seronegative was 4.5% (72.6%), 7.9% (73.4%), 10.1% (74.0%), 23.4% (79.6%) at 1, 2, 3 and 4 years after transplant, respectively. The loss of HAV antibodies was significantly associated with longer follow-up (P ¼ 0.0015), younger age (P ¼ 0.049) and acute graft-versus-host disease (P ¼ 0.035). As most reimmunization protocols start around day þ 365, in developing countries with similar HAV endemicity, BMT recipients should have serological screening before HAV vaccination and the inactivated vaccine should be advised to those seronegative.

show abstract

“…The reported Ab loss for Hepatitis A was 14 and 11.2% by Dignani et al and Godoi et al, respectively. 7,8 Table 3 summarizes these two studies. In both groups, the majority of the patients were adults, and in the first study, 86% of the patients had an autologous HSCT.…”

Section: Discussionmentioning

confidence: 99%

“…There is very little data in the literature regarding the loss of HAV Ab after HSCT. 7,8 This is the first study reporting seroprevalence and the incidence of loss of Ab for HAV in pediatric HSCT recipients. Moreover, it is the first study showing the relevance of donor immunity in the loss of HAV Ab after HSCT.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Significant loss of hepatitis A Ab after allogeneic hematopoietic SCT in pediatric patients

İnce

Ertem

İleri

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Loss of specific immunity after hematopoietic SCT (HSCT) is well documented for polio, measles, mumps and tetanus. There are limited studies reporting the loss of Hepatitis A virus immunity and no reports evaluating the effect of donor immunity on Hepatitis A virus (HAV) immunity loss after HSCT. A total of 49 of the 81 patients who received HSCT at the Ankara University Pediatric HSCT Unit from January 1997 to December 2006 had HAV serology tested before HSCT and were evaluated for seroprevalence, and 30 of 49 patients were evaluated for the loss of Ab and for the effect of donor immunity on the loss of HAV Abs. The seroprevalence before HSCT was 75.5%. Loss of Ab was detected in 43.5% (10/23) of the patients. The median time to loss of Ab was 12 months (12-32 months), and 60% of these patients were seronegative at 12 months after HSCT. After HSCT, 46.7% of the patients were seronegative. Loss of Ab was higher in the seronegative donor group (75 vs 26%). The loss of HAV Ab is high after allogeneic HSCT for pediatric patients. Reimmunization should be considered for the continuation of individual and community immunity. Further studies with larger study groups are warranted to clarify the role of donor immunity on the loss of HAV immunity.

show abstract

Loss of hepatitis A virus (HAV) antibodies after peripheral stem cell transplantation (PSCT)

Cited by 15 publications

References 18 publications

Diagnosis of Hepatitis A Virus Infection: a Molecular Approach

Diagnosis of Hepatitis A Virus Infection: a Molecular Approach

Loss of hepatitis A virus antibodies after bone marrow transplantation

Significant loss of hepatitis A Ab after allogeneic hematopoietic SCT in pediatric patients

Contact Info

Product

Resources

About